Copper(II) Cyclopeptides with High ROS-Mediated Cytotoxicity.

Area of Science:

• Coordination Chemistry
• Metallodrugs
• Cancer Therapeutics
• Oxidative Stress

Background:

• Copper(II) coordination complexes are investigated as anticancer agents due to their capacity to generate reactive oxygen species (ROS).
• Designing effective delivery systems for metal ions into cancer cells is crucial for therapeutic efficacy.

Purpose of the Study:

• To synthesize and characterize novel Cu(II) metallopeptide complexes for enhanced cancer treatment.
• To evaluate the efficacy of these complexes in increasing intracellular copper and ROS levels.
• To assess their anticancer activity and compare it with existing chemotherapeutics.

Main Methods:

• Synthesis and characterization of two Cu(II) metallopeptide systems (1/Cu(II) and 2/Cu(II)) using spectroscopic and electrochemical techniques.
• Inductively coupled plasma mass spectrometry (ICP-MS) for intracellular copper quantification.
• ROS generation assays, cell-viability assays (IC50 determination), and molecular modeling studies.

Main Results:

• Both metallopeptides efficiently transported Cu(II) into NCI/ADR-RES cancer cells.
• 1/Cu(II) significantly increased intracellular ROS levels, indicating oxidative stress induction.
• 1/Cu(II) and 2/Cu(II) exhibited strong anticancer activity, outperforming free peptides, Cu(II) alone, and cisplatin.

Conclusions:

• The novel Cu(II) cyclometallopeptide systems are effective intracellular Cu(II) transporters and ROS inducers.
• These metallopeptides demonstrate significant potential as metal-based anticancer therapeutic agents.
• The strategy of leveraging Cu(II) transport and ROS generation offers a promising avenue for cancer treatment development.